

August 10, 2016

Cheryl Reitz
Board Member and HCV+ Volunteer
HepCBC Hepatitis C Education and Prevention Society

Dear Cheryl,

Thank you for providing patient input on asunaprevir (Sunvepra) to the CADTH Common Drug Review.

Your group's input helped CADTH reviewers develop the review protocol by identifying important outcomes, and is discussed in the clinical report where relevant. The clinical report will shortly become available on CADTH's website.

A member of the Canadian Drug Expert Committee presented your input to provide the whole committee with patients' perspectives and to underscore unmet needs. Committee members reflected on how or whether the evidence under review addressed the issues identified by your group. A summary of the reasons for the recommendation is now available on our website.

CADTH reviewers and expert committee members found your input useful, particularly with regards to:

- Finding and interviewing three individuals with experience of asunaprevir. Thank you for sharing details of their disease status (genotype and fibrosis score), their treatment experiences and the impact of their recovery.
- Reminding CADTH and CDEC again of the fear, frustration, and hope, patients experience when waiting for access to interferon-free regimens. Your analogy of a 'drowning man who can see the shore' has been repeatedly used in committee meetings to underscore this idea.
- Sharing a comment on drug cost as barrier for access.

CADTH reviewers and the Canadian Drug Expert Committee members thank you for your time and effort in providing patients' perspectives. Patient input is an integral part of our review process and we appreciate your contribution.

Sincerely,



Sarah Berglas
Patient Engagement Officer, CADTH

cc: Frank Gavin, Public Member, CDEC; Allen Lefebvre, Public Member, CDEC; Brent Fraser, VP Pharmaceutical Reviews, CADTH.